Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59 results about "Oligodendroglia Cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
ActiveUS20170183627A1Low costComparable myelination potentialNervous disorderNervous system cellsProgenitorInduced pluripotent stem cell
Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to 04+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.
Owner:NEW YORK STEM CELL FOUND
Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells
Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and / or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and / or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
Owner:Q THERAPEUTICS
Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Neurons, astrocytes and oligodendrocytes differentiated from a mammalian pluripotent or neural stem cells exposed to a pyridine deriviative
InactiveUS8609413B2Reduce amountPromote differentiationBiocideNervous disorderPluripotential stem cellOligodendrocyte
A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes. These methods may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound.
Owner:RES DEVMENT FOUND
Method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis
The invention discloses a method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis, which comprises the following steps of 1) separating dMSCs, and carrying out passage on the dMSCs so as to obtain dMSCs primary cells; 2) moving the dMSCs primary cells obtained through separating to an amplification culture medium so as to carry out amplification; and 3) dropwise adding an engineering spinal cord saturated water solution into a physiological saline solution containing deep nerve nutriments, retinoic acid and Neuregulin, standing the obtained mixture, carrying out gradient alcohol dehydration on the mixture, and carrying out vacuum drying on the mixture; and infecting the dMSCs subjected to amplification by using a brain-derived neurenergen adenovirus expression vector, and inoculating cells to an engineering spinal cord material for culturing. In the method, tissue engineering spinal cords can effectively promote cell proliferation; and the differentiation rates of the tissue engineering spinal cords to nerve cells and oligodendroglia cells are respectively about 4.8% and 1.5% which are far higher than those of pure scaffold materials (the differentiation rates of pure scaffold materials to nerve cells and oligodendroglia cells are respectively 1.8% and 0.5%).
Owner:ARMY MEDICAL UNIV
Method for differentiating human induced pluripotent stem cells into oligodendrocytes, kit and application
The invention relates to the technical field of biology, in particular to a method for differentiating human induced pluripotent stem cells into oligodendrocytes, a kit and application. The method comprises the step of culturing stem cells by using at least one of the following culture media of a nerve induction complete culture medium, an N2 culture medium, a B27 culture medium and an OPC mature culture medium, and more preferably, the number of the oligodendrocytes induced by using the puerarin-containing OPC mature culture medium can be increased by 30% compared with the number of the oligodendrocytes induced by not using puerarin.
Owner:CHENGNUO REGENERATIVE MEDICINE TECH (ZHUHAI HENGQIN NEW AREA) CO LTD
Oligodendrocyte production from multipotent neural stem cells
InactiveUS20050244965A1Increase percentageMaximize productionOrganic active ingredientsNervous disorderOligodendrocyteInterleukin 5
This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
Owner:STEM CELL THERAPEUTICS
Recombinant vector for expressing light-sensitive type adenylate cyclase, applications and construction method of the recombinant vector and treating system for demyelination
The invention relates to a recombinant vector used for expressing light-sensitive type adenylate cyclase, applications and a construction method of the recombinant vector, and a treating system for demyelination. The recombinant vector comprises a viral vector, and a shuttle plasmid wrapped in the viral vector and carrying the gene sequence of the light-sensitive type adenylate cyclase. The gene sequence of the light-sensitive type adenylate cyclase comprises specific promoters of an oligodendroglia cell and a Schwann cell. The recombinant vector is adopted to infect a demyelination part so that the gene sequence of the light-sensitive type adenylate cyclase is only expressed in the oligodendroglia cell and the Schwann cell. Under stimulation of light, the cAMP level in the two cells can be adjusted directionally, thus promoting remyelination and stable myelin sheath growth and achieving an objective of treatment of the demyelination by cell specificity.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Construction of spinal cord tissues for repairing spinal cord injuries
The invention relates to a construction method of spinal cord tissues for repairing spinal cord injuries, in particular to a construction method for spinal cord tissues containing white matter structures on the periphery and grey matter structures in the center. When the construction method is used, the constructed spinal cord tissues containing white matter structure stem cell-derived oligodendroglia cells and grey matter structure stem cell-derived nerve cells are transplanted to transverse spinal cord injuries, and are integrated in a host neural network in a matching mode that a white matter structure corresponds to host white matters and a grey matter structure corresponds to host grey matters, so that the regeneration and functional repair of injured spinal cords are better promoted.
Owner:SUN YAT SEN UNIV
Method for separating and subculturing primary embryo-derived neural stem cell
The invention provides a method for separating and subculturing an embryo-derived primary neural stem cell, comprising the following steps: separating and culturing the primary neural stem cell, subculturing the primary neural stem cell, cloning and subculturing a single cell, carrying out induced differentiation, and carrying out indirect immunofluorescence detection. According to the method, a neural stem cell with the self-renewing and differentiating potential is separated from the fresh human embryonic cortex with an embryonic age of 12 weeks and cultured by adopting the serum-free culturing and single-cell cloning technology, and a large number of neural stem cells are formed three week later, wherein the neural stem cells have continuous cloning capacity and can subculature and express the neural nidogen antigen. The differentiated cells can express the specific antigens of the neuron cells, the colloid cells and oligodendroglia cells, and the problem that the embryo-derived neural stem cell is difficult to culture is solved.
Owner:陆华
Method for inducing human or animal somatic cells to neural stem cells
ActiveCN107435050AThere is no need to consider the risk of tumor formationHigh efficiency of directed differentiationSsRNA viruses negative-senseMicroencapsulation basedSomatic cellCulture mediums
The invention discloses a method for inducing human or animal somatic cells to neural stem cells and purpose of neural stem cells obtained by the method. By overexpression of transcription factor Ptf1a in separated human or animal somatic cells and culture in a culture medium containing EGF and bFGF, somatic cells can be induced to neural stem cells (iNSCs). The iNSCs obtained by the method has self-renewing capability, and can stably passage for 50 generations and above and maintain original cell characteristics. By culture in different in vitro differentiation mediums, the iNSCs can be efficiently differentiated to neurons, astrocytes and oligodendrocytes. By injecting the iNSCs in animal bodies, the injected cells can be integrated into nervous tissues of retina, cerebrum, etc. the method of the invention is simpler, safer and more efficient than previous methods. The iNSCs obtained by the method and further differentiated cells can be applied to cell models of nerve diseases, drug screening, stem cell treatment and the like.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Method for inductively differentiating umbilical cord mesenchymal stem cells into oligodendroglia cells
InactiveCN104774807AHas the function of inducing dischargeHigh differentiation efficiencyNervous system cellsSkeletal/connective tissue cellsOligodendroglia CellBiophysics
The invention discloses a method for inductively differentiating umbilical cord mesenchymal stem cells into oligodendroglia cells. A pre-inducing and inducing two-step combination method is adopted in the method, an optimized pre-inducing culture solution and an optimized inducing culture solution are prepared, saponins compounds are added to serve as an inducing object, and therefore the umbilical cord mesenchymal stem cells are successfully induced to be differentiated into the oligodendroglia cells; in addition, the differentiating proportion is higher.
Owner:中国人民解放军总医院第三医学中心
Induction of myelinating oligodendrocytes in human cortical spheroids
Owner:CASE WESTERN RESERVE UNIV
Personalized 3D neural culture system for generating human oligodendrocytes and studying myelination in vitro
Human pluripotent stem cells are differentiated in vitro into oligodendro-spheroids comprising oligodendrocytes for use in analysis, screening programs, and the like.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Application of glycyrrhizic acid to prepare drugs for promoting medullary sheath regeneration to restrain neurogenic inflammation
The invention discloses an application of glycyrrhizic acid to prepare drugs for promoting medullary sheath regeneration to restrain neurogenic inflammation. Experiment proves that the glycyrrhizic acid can effectively relieve inflammatory reactions and restrain demyelinating lesion, and can relieve development of diseases courses of acute and chronic experimental autoimmuneencephalomyelitis. Theglycyrrhizic acid can promote medullary sheath regeneration in a cuprizone-induced cuprizone demyelination model, an in vitro mechanism study finds that the glycyrrhizic acid can directly regulate a GSK-3 beta signal channel to induce the polarization of oligodendroglia precursor cells, so that the mature polarization of the oligodendroglia cells can be notably promoted, and the synthesis of medullary sheath protein is stimulated. A mechanism for promoting medullary sheath regeneration by the lycyrrhizic acid proves that a new basis is provided for treating demyelinating diseases and multiplesclerosis, and clinical-usable new medicines are provided for central nervous system demyelinating diseases and the like.
Owner:SHAANXI NORMAL UNIV
Myelin sheath oligodendroglia cell glycoprotein antibody kit and preparation method thereof
PendingCN110488022AEffective preservationImprove detection accuracyBiological testingCarrier proteinBiotin
The invention relates to the technical field of polypeptide chemistry and immunology and particularly discloses a myelin sheath oligodendroglia cell glycoprotein antibody kit. The kit is used for detecting the human MOG antibody by adopting a double-antigen sandwich method. The kit comprises a coating plate, a calibration product, a binding antigen, an enzyme conjugate, a quality control product,a color developing agent A, a color developing agent B, stop buffer and concentrated washing solution, wherein the coating plate is coated with an MOG coating antigen, the MOG coating antigen is prepared by coupling an S fragment in the human MOG epitope peptide with a carrier protein, the binding antigen is prepared by coupling a P fragment in the human MOG epitope peptide with a carrier protein,the MOG binding antigen is labeled with biotin, the NCBI (National Center of Biotechnology Information) login number of the human MOG epitope peptide is CAA52617.1. The kit is advantaged in that defects in the prior art are overcome, the content of MOG-Ab in the blood of a patient is accurately determined by adopting the double-antigen sandwich method, a doctor is helped to perform treatment, andthe kit is simple to operate, sensitive and rapid.
Owner:安徽恩禾生物技术有限公司
siRNA and recombinant vector for restraining MAG gene expression
InactiveCN103122349APromote regenerationImprove repair effectVector-based foreign material introductionDNA/RNA fragmentationMyelin glycoproteinAntiendomysial antibodies
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
RNA inhibitor and application thereof
PendingCN110951734AReduced activityReduce reproductionNervous disorderDNA/RNA fragmentationOligodendrocyteOligodendroglia Cell
The invention provides an RNA inhibitor and application thereof. The RNA inhibitor is an miRNA-17-5p inhibitor and has an miRNA-17-5p inhibition sequence. The miRNA-17-5p inhibitor can be used for inhibiting activation and proliferation of astrocytes after spinal cord injuries. According to the RNA inhibitor, oligodendrocytes after the spinal cord injuries are applied to generating a large quantity of exosomes carrying miR-17-5p, the exosomes can be taken in by the astrocytes, and thus activation characteristics of the astrocytes are promoted; and an antagonist of the miR-17-5p is designed, thus, a purpose of reducing astrocyte excessive proliferation is achieved, and an effective therapeutic target is provided for treating the spinal cord injuries.
Owner:NANTONG UNIVERSITY
Targeting extracellular vesicle as well as preparation method and application thereof
PendingCN113528580AHigh drug loading rateAccurate targetPolypeptide with localisation/targeting motifCell dissociation methodsTherapeutic effectPharmaceutical Substances
The invention relates to the technical field of biological drug carrier preparation, and particularly discloses a targeting extracellular vesicle as well as a preparation method and application thereof. The method comprises the following steps: constructing an LV-Lc-PDGFA fusion expression lentiviral vector, infecting neural stem cells, constructing a stably transfected cell line NSC-LV-Lc-PDGFA, and positioning an expressed exogenous ligand PDGFA on the surface of an extracellular vesicle membrane, so that the targeting capability of the extracellular vesicles on the oligodendroglia lineage cells is improved. The extracellular vesicle with the membrane surface expressing the PDGFA small peptide has high targeting property, can be used as a drug carrier, and has a good treatment effect on demyelination diseases.
Owner:SHAANXI NORMAL UNIV
Myelin oligodendrocyte glycoprotein antibody kit and detection method thereof
ActiveCN112611874AEffective preservationEfficient detectionDisease diagnosisBiological testingEnzyme bindingMyelin sheaths
The invention belongs to the technical field of polypeptide chemistry and immunology, and particularly relates to a myelin oligodendrocyte glycoprotein antibody kit, which takes recombinant protein coded by an extracellular region sequence of a human myelin oligodendrocyte glycoprotein gene as a coating antigen. The invention also provides a detection method of the kit. The method comprises the following steps: separating to obtain an antigen-to-be-detected antibody-binding antigen-MOG enzyme conjugate compound, adding a color developing agent A and a color developing agent B, adding a stop solution, detecting by using a microplate reader, and calculating the concentration of MOG-Ab according to the absorbance OD value and a standard curve. According to the invention, the defects in the prior art are overcome,the myelin oligodendrocyte glycoprotein antibody in serum can be quickly and specifically detected, and the kit is good in reaction specificity, high in sensitivity, simple to operate, low in cost, stable and reliable in reaction result and easy to observe.
Owner:安徽恩禾生物技术有限公司
Method for inducing umbilical cord mesenchymal stem cells to differentiate into oligodendrocytes
InactiveCN104774807BHas the function of inducing dischargeHigh differentiation efficiencyNervous system cellsSkeletal/connective tissue cellsOligodendrocyteOligodendroglia Cell
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL
High-low density anchorage-dependent cell culturing method of old embryonic age neural stem cells
The invention provides a high-low density anchorage-dependent cell culturing method of old embryonic age neural stem cells. The method comprises the steps of: separation and culture of the cortex neural stem cells, culture of the neural stem cells by the high-low density anchorage-dependent cell culturing method, subculture of the neural stem cells, monoplast cloning of the neural stem cells, differentiation culture of the neural stem cells and detection by an immumofluorescence method. According to the method provided by the invention, self-renewal neural stem cells with the differentiative potential are separated and cultured from an embryonic human brain cortex which is 13 weeks old by serum-free culture and monoplast clone technology. A plenty of neural stem cells are cultured by the high-low density anchorage-dependent cell culturing method, wherein the density decreases gradually. The cells have the continuous cloning capacity, can be subcultured, and express neural nidogen antigen. Differentiated cells express the specific antigens of neuron, gliocyte and oligodendroglia cell, so that the problem that embryo neural stem cells are hard to culture is solved.
Owner:陆华
Application of quetiapine fumarate in preparing medicine for treating glioma
InactiveCN105147700AGrowth inhibitionPromote growthOrganic active ingredientsAntineoplastic agentsRecurrent GliomaIn vivo
The invention relates to the field of antitumor drugs, and in particular relates to an application of quetiapine fumarate in preparing a medicine for treating glioma. Through in-vivo and in-vitro experiments, the effects of resisting glioma and glioma stem cells of quetiapine fumarate (KUI) and the effects obtained by mixing KUI with chemotherapy drug temozolomide (TMZ) are investigated; quetiapine fumarate can inhibit growth of glioma, and promote the glioma stem cells to express markers of oligodendroglia cells, and after being mixed with TMZ for application, quetiapine fumarate increases the sensitivity of the glioma cells for temozolomide, and the inbibiting effect is better; after temozolomide acts, quetiapine fumarate can delay the growth of recurrent glioma; quetiapine fumarate can promote the glioma stem cells to differentiate and mature towards the oligodendroglia like cells by taking the glioma stem cells as the action target. Therefore, quetiapine fumarate can be used for preparing the medicine for treating glioma, and achieves good effects for treating and prognosis of glioma.
Owner:李成仁
Method for efficiently and rapidly reprogramming somatic cells into neural stem cells and application thereof
ActiveCN112608904ARapid expansionShort induction timeNervous disorderCulture processReprogrammingSomatic cell
One of the purposes of the invention is to provide a method for efficiently and rapidly reprogramming somatic cells into neural stem cells. The method comprises the following steps: separating, extracting and amplifying somatic cells; transfecting a gene knock-down vector or a gene knock-out vector; carrying out multiplication culture on the neural stem cells; the gene knock-down vector or the gene knock-out vector comprises shRNA, siRNA, a CRISPR gene editing vector or a related microRNA inhibitor for blocking let-7 genes. According to the present invention, the expression of one microRNA-let-7b is knocked down or knocked out without introducing any exogenous gene, and the neural stem cells are successfully induced from fibroblasts, such that the sufficient amount of cells required by transplantation can be generated through amplification within a short time, and the cells are genetically stable and can be differentiated to form neurons, astrocytes and oligodendrocytes; more than 20 generations of neural stem cells can be amplified, and no induced tumor is formed after the neural stem cells are transplanted to mice.
Owner:BINZHOU MEDICAL COLLEGE
Synthetic modified Olig2 mRNA and application thereof
PendingCN113278624AFast and efficient directed differentiationHigh ability to induce differentiationNervous disorderMicroencapsulation basedOLIG2Phosphorylation
The invention relates to synthetic modified Olig2mRNA and application thereof, and belongs to the technical field of stem cell induced differentiation. The protein translated by the Olig2mRNA is always in a dephosphorylation state. By transfecting neural precursor cells derived from human induced pluripotent stem cells, rapid and efficient directional differentiation of the human induced pluripotent stem cells to oligodendrocytes is realized, and the designed and modified Olig2mRNA shows higher efficiency of induced differentiation than wild type Olig2mRNA. By utilizing the method disclosed by the invention, the induced pluripotent stem cells can be quickly differentiated into the oligodendrocytes, the risk of gene integration of the oligodendrocytes induced based on overexpression of a transcription factor SOX10 in the past can be avoided, and the method is more beneficial to the development of clinical tests. The rapid induction of oligodendrocytes derived from the human induced pluripotent stem cells provides a technical support for treating myelin sheath injury type neurodegenerative diseases through transplantation of oligodendrocyte precursor cells in the future.
Owner:SUN YAT SEN UNIV SHENZHEN +1
AAV vectors targeted to oligodendrocytes
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Application of TRPA1 inhibitor in preparation of medicine for treating multiple sclerosis
InactiveCN111481674AInhibition of calcium ion influxInhibition of inflowNervous disorderAmine active ingredientsPhospholipidCytoplasm
The invention discloses an application of a TRPA1 inhibitor in preparation of a medicine for treating multiple sclerosis. The TRPA1 inhibitor can be used for preparing a medicine for treating multiplesclerosis caused by lysophosphatidylcholine (LPC). According to the application, by establishing an OLN-93 oligodendrocyte oxidative stress and cytotoxicity model, the expression of TRPA1 on OLN-93 oligodendrocytes and oxidative stress and cell damage caused by participation of TRPA1 in LPC induction are explored. Research results show that the TRPA1 inhibitor can significantly inhibit calcium ion internal flow in cytoplasm and mitochondria, significantly reduce mitochondrial active oxygen production, significantly inhibit mitochondrial membrane potential reduction, significantly inhibit NO production, significantly inhibit superoxide increase and effectively inhibit oligodendrocyte toxicity increase. Therefore, it is possible to treat demyelinating diseases such as multiple sclerosis caused by LPC using an inhibitor of TRPA1.
Owner:广州浚远康生物科技有限公司
Method for preparing tissue engineering spinal cord by using ancestral cells originated from skin
ActiveCN103396984APromote proliferationArtificial cell constructsVertebrate cellsNeuregulinNeurotrophin-3
The invention discloses a method for preparing a tissue engineering spinal cord by using ancestral cells originated from skin. The method comprises the following steps: 1) separating SKPs, and passing to obtain SKPs primary cells; 2) immigrating the SKPs primary cells separated to an amplification culture medium for amplification; and 3) preparing the tissue engineering spinal cord, and dropwise adding saturated aqueous liquor of a tissue engineering spinal cord material to physiological saline liquor containing Neurotrophin-3(NT3), retinoic acid and Neuregulin; infecting the amplified SKPs by a brain-derived neurenergen adenovirus expression vector, and inoculating the cells to the tissue engineering spinal cord material to cultivate. In the method disclosed by the invention, the tissue engineering spinal cord can effectively promote cell proliferation, and the differentiating proportions of the tissue engineering spinal cord toward nerve cells and oligodendroglia cells are about 4.8% and 1.5% which are far greater than 1.8% and 0.5% of a pure support material.
Owner:ARMY MEDICAL UNIV
Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector
PendingCN111699259ALow specificityInhibit expressionOrganic active ingredientsNervous disorderPlp1 geneBase J
Owner:NAT CENT OF NEUROLOGY & PSYCHIATRY +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com